Latin America (LA) has a population of~645 million people distributed over 33 countries with marked political, cultural and economic differences. In LA, patients with inherited neuromuscular diseases (NMDs) often do not have access to specialized medical centers and many of them go undiagnosed. General management and care of spinal muscular atrophy (SMA) patients in the region varies due to heterogeneous health care. An active generation of young clinical neurologists is being trained for the specialized care of SMA and other neuromuscular (NM) patients, both in the private and public sectors. The Euro-LatinAmerican Summer School of Myology (EVELAM) as well as efforts of professionals at large public centers in the major cities of LA have a leading role in this development. Different regional academic-scientific organizations as well as the expanding number of telethon centers and the creation of parent organizations, mostly concerning SMA, all together are contributing to the increased quality of the management of NMD patients. Over the past years, academic and clinical research, as well as the establishment of qualified centers for the molecular testing of NMD are pushing forward the creation of patient registries and the development of specific clinical trials, with Argentina and Brazil having a major role in this field. Nevertheless, increased awareness and further training of specialized health professionals are necessary to reach patients that are currently lacking care throughout the region.
INTRODUCTION
Neuromuscular diseases (NMD) are a heterogeneous group of disorders characterized by involvement of different components of the peripheral nervous system. Spinal muscular atrophy (SMA) is part of this group and is characterized by degeneration of the motor neurons in the anterior horn of the spinal cord. Over the past two decades, knowledge on the disease has greatly increased leading to the development of new treatments 1 and the approval of the promising new drug Spinraza by the FDA (Food and Drug Administration, USA) at the end of 2016.
Latin America (LA), with a current population of around 645 million people, is an extensive and heterogeneous continent, with marked political and cultural differences. Although Spanish is the spoken language in most of the LA countries, about 30% of the population of LA live in Brazil and speak Portuguese. The heterogeneity is recognized in the region as a whole, but also within countries. Many patients with SMA and other NMD currently receive no treatment at all. Although in LA, exact numbers are unknown, considering the worldwide incidence of SMA-1 per 6000-10 000 live births 2,3 -very probably many patients go undiagnosed. People living in remote rural areas and indigenous communities frequently have limited access to conventional health systems and often consult traditional healers. In contrast, in certain regions, especially in large cities in Argentina, Brazil, Chile and Mexico, care is comparable to that in major North American and European cities. Referral and counterreferral services in the region are rare.
MAJOR DEVELOPMENTS IN NEUROMUSCULAR DISEASES IN LATIN AMERICA
Over the past decades, leading clinical neurologists from Argentina, Brazil and Mexico have been pioneers in the development of diagnostic methods for, and management of patients with NMD in LA. Subsequently, new generations have assumed their role developing specialized care for these patients in private and public centers throughout the continent. The young LA specialists were mostly trained at the annual Summer School of Myology, organized at the Institute of Myology in Paris since 1998. In addition, since 2007, the Euro-Latin-American Summer School of Myology (EVELAM) is held yearly in different countries of LA with the participation of lecturing local and foreign experts in NMD. The school is attended by 100-150 clinicians and researchers (that is, neurologists, pathologists, geneticists, physical therapists and so on) from different LA countries. The aim of EVELAM is to disseminate and increase the knowledge on and awareness of NMD in the region. Since its beginnings, EVELAM has been an important academic and scientific resource for the training of health professionals involved in the care of patients with NMD. 4 Over the years, several clinical studies of LA SMA patients have been published in the Spanish and Portuguese literature. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Genetic research on NMD, involving linkage analyses and gene characterization studies of large NMD families was initiated in Brazil. 18 Subsequently, a growing number of research groups started to work in basic and translational research on SMA and NMD, mostly in Argentina, Brazil, Chile, Mexico and Uruguay, and often in collaboration with centers in Europe. It is expected that these studies will encourage other countries in the region to start specific clinical and research programs regarding NMD.
In Argentina, the first molecular studies of the SMN1 gene were performed in 1997 at CIQUIBIC-CONICET, Universidad Nacional de Cordoba. At this laboratory, molecular testing of several other NMD and the genetic diagnosis of SMA was performed for patients both in Argentina and neighbouring countries. As part of these studies, a rare point mutation in the SMN1 gene was recognized in a young type III SMA patient from Argentina. 19 In 1998, molecular diagnosis of SMA was started at the molecular diagnosis laboratory at Hospital JP Garrahan, a public reference hospital in Buenos Aires, Argentina. At the same time, Brazilian groups also started clinical research in SMA patients. 20 Since 2011, SMN2 copy-number and SMA carrier studies have been performed in laboratories in Argentina and Brazil. 21 In 2006, a program was set up for patient care, teaching and research in NMD at Hospital Garrahan in order to improve the quality of life of SMA patients. A dedicated and trained interdisciplinary team was set up, consisting of a neurologist, physical therapist, pathologist, clinician, geneticist, palliative care specialist, nutritionist and endocrinologist, among others. The team covers different aspects of the neuromuscular (NM) patient ranging from diagnosis to transition to adult care and end-of-life palliative care for the patients and their families. The consensus statement for the standard of care in SMA by Wang et al. 22 is used.
PARENT ORGANIZATIONS, PATIENT REGISTRIES AND CLINICAL TRIALS IN LATIN AMERICA
Families of patients with different NMD have set up parent organizations. Among them, parents of children with SMA founded in 2004 a non-profit association for families of SMA patients in Argentina (FAME; www.fameargentina.com.ar/). FAMEArgentina has participated in yearly international meetings of SMA families-CURE SMA. This parent association has been a strong advocate for and sponsor of the development of early diagnosis, care and research, allowing for health professionals in the field to attend international meetings and online courses and participating in the organization of training symposia. Similar parent organizations were created in Brazil, Chile, Mexico, Venezuela and Uruguay. Between 2008 and 2009, in Argentina, FAME locally supported and coordinated 'CARNI-VAL', 23 the first pharmacological trial to be held in LA for the treatment of SMA patients. It was a multicenter study coordinated together with the Project Cure SMA including centers in the United States, Canada and Argentina. The protocol included baseline visits and clinical assessments with a total study duration of 12 months. Fourteen patients were enrolled in the trial. In Argentina, some patients had to travel long distances (sometimes 41000 miles) to attend the visits at Sanatorio Allende, in the city of Cordoba. CARNI-VAL led to additional studies on SMA in Argentina.
In 2016, Hospital Garrahan in Buenos Aires, Argentina, became one of the study sites of Nurture, an open-label study to evaluate the efficacy, safety, tolerability and pharmacokinetics of multiple intrathecal doses of ISIS 396443 in pre-symptomatic subjects with genetically diagnosed SMA.
Another important aim in the care for SMA patients and their families in LA was the development of a local registry for patients with NMD. Currently, the Argentine registry includes patients with SMA and DMD as part of TREAT-NMD. These data contributed to a worldwide epidemiological study on SMA. 24 Local registries of patients with SMA and NMD that are part of TREAT-NMD exist in Chile and Mexico. An additional registry is being developed in Brazil.
In the region, Chile has strongly contributed to the local knowledge on NMD by the dissemination of a Spanish version of the SOC-based TREAT-NMD guidelines.
Interestingly, the worldwide-distributed 'telethon' organizations (that is, a televised fundraising event that lasts many hours or even days) were designed for LA by the Chilean Mario Kreutzberger ('Don Francisco') with the aim to develop services for rehabilitation and social inclusion of children and adolescents with disabilities. The first telethon was held in Chile in 1978. The interest in and impact of telethon as a fundraising project to help patients with disabilities quickly expanded to other countries in LA as well as Europe, Canada and the United States. Currently, 12 American countries have telethon organizations with 145 rehabilitation centers and support therapy units built in Chile, USA, Colombia, Paraguay, Peru, Puerto Rico, Uruguay, El Salvador, Mexico, Honduras, Nicaragua and Guatemala. In Brazil, in 1950, the Associação de Assistência Ã Criança Deficiente (AACD) or Association for the Welfare of Disabled Children (https://aacd. org.br/) was founded as a center of excellence for rehabilitation of patients with disabilities, and in 1998, became a telethonassociated organization. Since then, 12 rehabilitation centers and a hospital for rehabilitation operations and exams have been created.
Around 230 000 children, adolescents and adults with disabilities receive annual assistance through this system in LA. Over the past years, many LA telethon rehabilitation centers have included a specific multidisciplinary program for the study, diagnosis and physical management of patients with NMD and their families as well as a specific registry of these patients. The participation of the medical staff from these centers in the annual EVELAMs as well as the biannual meetings of ORITEL contribute to the general awareness and specific care of NM patients and the creation of an LA framework for future qualified medical trials and NM patient follow-up.
In addition to public and private medical centers specialized in NM patients and the activities of EVELAMs and telethons, there are other academic and scientific organizations with the mission to promote awareness, advancement, diffusion and research in the field of NMD in LA. Among these, SOLANE (Latin-America Society of Neuromuscular diseases; http://www.websolane.org/) and GrELAM (Euro-Latin American Group of Myology) have relatively recently been created to encourage exchange of scientific information and multidisciplinary collaboration between individuals, organizations, societies and study groups concerning NMD and related disciplines among countries in the region.
In spite of these efforts in LA, the treatment gap-the difference between people with SMA and NMD and the patients who are actually treated-is still wide. In many countries, no specialized care is available. To reach patients throughout the region, adequate training of specialized health professionals is necessary. There is a need to create new awareness of the disease through the organization of courses for neurologists treating NM patients. In the coming years, national registries should be started in other LA countries. Referral and counter-referral programs should be in place for consultation and possible referral of patients with NMDs to tertiary-care centers.
CONCLUSION
Recently, much has been happening in the field of myology in LA. Many aspects concerning the diagnosis and management of patients, however, remain to be covered. Most important is the training of young myologists who are able to adequately identify individuals with NMD and deliver cost-effective care. New challenges lie in next-generation sequencing (that is, exome studies and gene panel analyses) and their adequate interpretation associated with clinical findings. Concerning the multidisciplinary management of NM patients, while in some countries specialized follow-up is available, in other countries the resources for appropriate care need to be improved. A referral and counter-referral program should be in place for consultation and possible referral of patients with NMD to tertiary-care centers.
